Peptide Anti-Aging Face Cream

Product Description

Phillips’s Peptide Wrinkle Remover contain the patented ingredient Argireline. Argireline has a unique ability to reduce wrinkles and aging lines on the face and neck.

Phillips’s Peptide formula contains high amounts of this peptide. The information on the Argireline is found below

ARGIRELINE�
A New Anti-Wrinkle Peptide
(Acetyl Hexapeptide-3)
Argireline: Inhibits Wrinkle Formation
Argireline is a unique new peptide that both reduces the degree of existing facial wrinkles and has been demonstrated effective
against their development. It�s been shown to inhibit the formation of the SNARE complex as well as catecholamine release.
These inhibitions confer anti-aging activity on Argireline; they closely relate to the basic biochemical mechanisms of wrinkle
formation.

Controlled studies have also demonstrated that facial wrinkle depth can be reduced, especially in the forehead and around the eyes, and that Argireline can prevent apparent facial skin aging. Skin topographic analysis performed on healthy female volun-teers confirmed the validation of the proposed biochemical mechanism of action.

Causes of Facial Wrinkling

Facial wrinkling associated with aging is caused � and exacerbated � by many factors. Beyond the physiological pathways, molecular mechanisms involved in facial aging include changes in collagen conformation, elastin polypeptide degradation, and problems of the skin�s lipid matrix. Recent studies clearly establish that these changes can be significantly reduced by inhibiting SNARE complex formation, a core of membrane proteins that mediate neuronal exocytosis. Their inhibition by short synthetic peptides can decrease facial wrinkle formation, and thereby the appearance of aging. The overproduction and release of cate-cholamines also encourages the formation of wrinkles and fine lines.

The Technology

Argireline�s specific sequence wasshown to inhibit the SNARE complex formation and catecholamine release. Once identified, it was synthesized by solid phase peptide synthesis and then purified and characterized.

Argireline solution was found to inhibit vesicle docking by preventing formation of the essential ternary SNARE Complex. Inhibi -tion of noradrenaline and adrenaline release was also demonstrated in a second in vitro study.

In vivo tests further demonstrated the benefits of Argireline solution. Facial topography analysis (for measuring the effectiveness of an O/W emulsion containing 10% Argireline solution) was performed using silicon replicas from around the eyes at 0, 15 and 30 days of a twice-a-day treatment regimen. Analyses of the imprints were performed by confocal laser scanning microscopy. It was observed that the severity of wrinkles around the eyes decreased up to 17% after 15 days of treatment and up to 27% after 30 days of treatment, substantiating the proposed biochemical mechanism hypothesis.

Argireline Efficacy Testing

The anti-wrinkle effect of Argireline solution was ascertained in two different in vitro tests directly related to the formation of wrinkles in the epidermis as well as a separate in vivo test performed on healthy human volunteers.

IN VITRO TESTING SNARE complex modulation in chromaffin cells

This test evaluates inhibition of the SNARE complex formed by peptides from the N-terminus of SNAP-25 (synaptosome-asso-ciated protein of 25kDa). Argireline solution modulates SNARE complex formation at concentrations in the mM range Chromaffin cells were prepared and further separated from erythrocytes and other impurities by centrifugation gradient. Cells were maintained in monolayer cultures. The ternary SNARE complex was precipitated and incubated with Argireline and other related peptides, or without them (as a control). Immunocomplexes were analyzed under non-reducing conditions and immuno-blotted with an anti-syntaxin mAb. Argireline proved to modulate vesicle docking by attenuating the formation of the essential ternary SNARE complex. Modulation of catecholamine release in chromaffin cells Inhibition of the release of catecholamines was determined by monitoring the neurotransmitters adrenaline and noradrenaline.

Chromaffin cells were incubated with tritiated noradrenaline/adrenaline and Argireline. The release of catecholamines, as well as the total cell content, was determined by liquid scintillation counting. The significant modulation of both neurotransmitters at nM concentrations of Argireline solution is a clear indicator of the potent anti-wrinkle activity of this hexapeptide

ARGIRELINE�
A New Anti-Wrinkle Peptide
(Acetyl Hexapeptide-3)
Argireline: Inhibits Wrinkle Formation

Argireline is a unique new peptide that both reduces the degree of existing facial wrinkles and has been demonstrated effective
against their development. It?s been shown to inhibit the formation of the SNARE complex as well as catecholamine release.
These inhibitions confer anti-aging activity on Argireline; they closely relate to the basic biochemical mechanisms of wrinkle
formation.

Controlled studies have also demonstrated that facial wrinkle depth can be reduced, especially in the forehead and around the
eyes, and that Argireline can prevent apparent facial skin aging. Skin topographic analysis performed on healthy female volun-teers
confirmed the validation of the proposed biochemical mechanism of action.

Causes of Facial Wrinkling

Facial wrinkling associated with aging is caused � and exacerbated � by many factors. Beyond the physiological pathways,
molecular mechanisms involved in facial aging include changes in collagen conformation, elastin polypeptide degradation, and
problems of the skin�s lipid matrix. Recent studies clearly establish that these changes can be significantly reduced by inhibiting
SNARE complex formation, a core of membrane proteins that mediate neuronal exocytosis. Their inhibition by short synthetic
peptides can decrease facial wrinkle formation, and thereby the appearance of aging. The overproduction and release of cate-cholamines
also encourages the formation of wrinkles and fine lines.

The Technology

Argireline?s specific sequence wasshown to inhibit the SNARE complex formation and catecholamine release. Once identified,
it was synthesized by solid phase peptide synthesis and then purified and characterized.
Argireline solution was found to inhibit vesicle docking by preventing formation of the essential ternary SNARE Complex. Inhibi -tion
of noradrenaline and adrenaline release was also demonstrated in a second in vitro study.
In vivo tests further demonstrated the benefits of Argireline solution. Facial topography analysis (for measuring the effectiveness
of an O/W emulsion containing 10% Argireline solution) was performed using silicon replicas from around the eyes at 0, 15 and
30 days of a twice-a-day treatment regimen. Analyses of the imprints were performed by confocal laser scanning microscopy. It
was observed that the severity of wrinkles around the eyes decreased up to 17% after 15 days of treatment and up to 27% after
30 days of treatment, substantiating the proposed biochemical mechanism hypothesis.

Argireline Efficacy Testing

The anti-wrinkle effect of Argireline solution was ascertained in two different in vitro tests directly related to the formation of
wrinkles in the epidermis as well as a separate in vivo test performed on healthy human volunteers.

IN VITRO TESTING SNARE complex modulation in chromaffin cells

This test evaluates inhibition of the SNARE complex formed by peptides from the N-terminus of SNAP-25 (synaptosome-asso-ciated
protein of 25kDa). Argireline solution modulates SNARE complex formation at concentrations in the mM range (see Fig. 1).
Chromaffin cells were prepared and further separated from erythrocytes and other impurities by centrifugation gradient. Cells
were maintained in monolayer cultures. The ternary SNARE complex was precipitated and incubated with Argireline and other
related peptides, or without them (as a control). Immunocomplexes were analyzed under non-reducing conditions and immuno-blotted
with an anti-syntaxin mAb.

Argireline proved to modulate vesicle docking by attenuating the formation of the essential ternary SNARE complex.
Modulation of catecholamine release in chromaffin cells

Inhibition of the release of catecholamines was determined by monitoring the neurotransmitters adrenaline and noradrenaline.
Chromaffin cells were incubated with tritiated noradrenaline/adrenaline and Argireline. The release of catecholamines, as well as
the total cell content, was determined by liquid scintillation counting. The significant modulation of both neurotransmitters at nM
concentrations of Argireline solution is a clear indicator of the potent anti-wrinkle activity of this hexapeptide (see Fig. 2).

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.